JP2017528520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528520A5 JP2017528520A5 JP2017530972A JP2017530972A JP2017528520A5 JP 2017528520 A5 JP2017528520 A5 JP 2017528520A5 JP 2017530972 A JP2017530972 A JP 2017530972A JP 2017530972 A JP2017530972 A JP 2017530972A JP 2017528520 A5 JP2017528520 A5 JP 2017528520A5
- Authority
- JP
- Japan
- Prior art keywords
- methoxy
- carbonitrile
- pyridine
- benzofuran
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000012216 imaging agent Substances 0.000 claims description 102
- -1 cyano, methyl Chemical group 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 30
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 238000012636 positron electron tomography Methods 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 208000037273 Pathologic Processes Diseases 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 230000009054 pathological process Effects 0.000 claims description 4
- NCQIEJTXMLFJRY-UHFFFAOYSA-N (2-pyridin-3-yl-1,3-benzoxazol-5-yl)methanol Chemical compound N=1C2=CC(CO)=CC=C2OC=1C1=CC=CN=C1 NCQIEJTXMLFJRY-UHFFFAOYSA-N 0.000 claims description 3
- IMJGUZBNDBLOAK-UHFFFAOYSA-N 2-(3-bromopyridin-4-yl)-1,3-benzothiazol-6-ol Chemical compound S1C2=CC(O)=CC=C2N=C1C1=CC=NC=C1Br IMJGUZBNDBLOAK-UHFFFAOYSA-N 0.000 claims description 3
- CFGQDXDPCSUZSH-UHFFFAOYSA-N 2-(3-bromopyridin-4-yl)-6-methoxy-1,3-benzothiazole Chemical compound S1C2=CC(OC)=CC=C2N=C1C1=CC=NC=C1Br CFGQDXDPCSUZSH-UHFFFAOYSA-N 0.000 claims description 3
- IZYUYEILENMPDT-UHFFFAOYSA-N 2-(3-methylphenyl)-1,3-benzoxazol-5-amine Chemical compound CC1=CC=CC(C=2OC3=CC=C(N)C=C3N=2)=C1 IZYUYEILENMPDT-UHFFFAOYSA-N 0.000 claims description 3
- UTDCCOHXAPBGKO-UHFFFAOYSA-N 2-(3-methylphenyl)-[1,3]oxazolo[5,4-b]pyridin-6-amine Chemical group CC1=CC=CC(C=2OC3=NC=C(N)C=C3N=2)=C1 UTDCCOHXAPBGKO-UHFFFAOYSA-N 0.000 claims description 3
- ITFJBVWVZSRNHZ-UHFFFAOYSA-N 2-pyridin-3-yl-1,3-benzoxazol-5-amine Chemical compound N=1C2=CC(N)=CC=C2OC=1C1=CC=CN=C1 ITFJBVWVZSRNHZ-UHFFFAOYSA-N 0.000 claims description 3
- ZCTHPTXYNUMPGE-UHFFFAOYSA-N 2-pyridin-4-yl-1,3-benzoxazol-5-amine Chemical compound N=1C2=CC(N)=CC=C2OC=1C1=CC=NC=C1 ZCTHPTXYNUMPGE-UHFFFAOYSA-N 0.000 claims description 3
- ZIKYQHVPEWMFIU-UHFFFAOYSA-N 4-(6-methoxy-1,3-benzothiazol-2-yl)benzonitrile Chemical compound S1C2=CC(OC)=CC=C2N=C1C1=CC=C(C#N)C=C1 ZIKYQHVPEWMFIU-UHFFFAOYSA-N 0.000 claims description 3
- FBZBVYGYNCRHEM-UHFFFAOYSA-N 6-methoxy-2-(2-methoxyphenyl)-1,3-benzothiazole Chemical compound S1C2=CC(OC)=CC=C2N=C1C1=CC=CC=C1OC FBZBVYGYNCRHEM-UHFFFAOYSA-N 0.000 claims description 3
- SEQBOWWCVROFEL-UHFFFAOYSA-N BrC1=C(C#N)C(=CC=C1)C=1OC2=C(C=1)C=C(C=C2)OC Chemical compound BrC1=C(C#N)C(=CC=C1)C=1OC2=C(C=1)C=C(C=C2)OC SEQBOWWCVROFEL-UHFFFAOYSA-N 0.000 claims description 3
- LRNPUZOVQWPHOQ-UHFFFAOYSA-N BrC1=C(OC2=C1C=C(C=C2)OC)C1=CC=NC=C1 Chemical compound BrC1=C(OC2=C1C=C(C=C2)OC)C1=CC=NC=C1 LRNPUZOVQWPHOQ-UHFFFAOYSA-N 0.000 claims description 3
- HJGPLBVVFGORQM-UHFFFAOYSA-N BrC=1C=C2C(=NC=1)OC(=C2)C1=C(C#N)C=CC=C1 Chemical compound BrC=1C=C2C(=NC=1)OC(=C2)C1=C(C#N)C=CC=C1 HJGPLBVVFGORQM-UHFFFAOYSA-N 0.000 claims description 3
- XBBUCNQMPJHZDQ-UHFFFAOYSA-N BrC=1C=CC(=C(C#N)C=1)C=1OC2=C(C=1)C=C(C=C2)OC Chemical compound BrC=1C=CC(=C(C#N)C=1)C=1OC2=C(C=1)C=C(C=C2)OC XBBUCNQMPJHZDQ-UHFFFAOYSA-N 0.000 claims description 3
- VYARPIZJKMXUOL-UHFFFAOYSA-N C(#C)C=1C=NC=CC=1C=1OC2=C(C=1)C=C(C=C2)OC Chemical compound C(#C)C=1C=NC=CC=1C=1OC2=C(C=1)C=C(C=C2)OC VYARPIZJKMXUOL-UHFFFAOYSA-N 0.000 claims description 3
- DGVQJSQXYQGFOH-UHFFFAOYSA-N CN(C)C1=CC=C2N=C(SC2=C1)C1=C(C=NC=C1)C#N Chemical compound CN(C)C1=CC=C2N=C(SC2=C1)C1=C(C=NC=C1)C#N DGVQJSQXYQGFOH-UHFFFAOYSA-N 0.000 claims description 3
- LKJHDMQGRRSTQA-UHFFFAOYSA-N CN(C)CC1=C(C#N)C(=CC=C1)C=1OC2=C(C=1)C=C(C=C2)OC Chemical compound CN(C)CC1=C(C#N)C(=CC=C1)C=1OC2=C(C=1)C=C(C=C2)OC LKJHDMQGRRSTQA-UHFFFAOYSA-N 0.000 claims description 3
- ZESVXGNAJFLKLO-UHFFFAOYSA-N CN(C)CC1=CC(=C(C#N)C=C1)C=1OC2=C(C=1)C=C(C=C2)OC Chemical compound CN(C)CC1=CC(=C(C#N)C=C1)C=1OC2=C(C=1)C=C(C=C2)OC ZESVXGNAJFLKLO-UHFFFAOYSA-N 0.000 claims description 3
- KDTVAGLGTBTSGG-UHFFFAOYSA-N CNC1=C(C=CN=C1)C1=NC2=CC=C(OC)C=C2S1 Chemical compound CNC1=C(C=CN=C1)C1=NC2=CC=C(OC)C=C2S1 KDTVAGLGTBTSGG-UHFFFAOYSA-N 0.000 claims description 3
- XIHHXXIPBVQUSO-UHFFFAOYSA-N COC1=CC2=C(C=C1)N=C(O2)C1=C(C=CC=C1)C#N Chemical compound COC1=CC2=C(C=C1)N=C(O2)C1=C(C=CC=C1)C#N XIHHXXIPBVQUSO-UHFFFAOYSA-N 0.000 claims description 3
- LTJFMMOYDPGMSU-UHFFFAOYSA-N COC1=CC2=C(C=C1)N=C(O2)C1=C(C=NC=C1)C#N Chemical compound COC1=CC2=C(C=C1)N=C(O2)C1=C(C=NC=C1)C#N LTJFMMOYDPGMSU-UHFFFAOYSA-N 0.000 claims description 3
- PAYAXQUHENCLPC-UHFFFAOYSA-N COC1=CC2=C(C=C1)N=C(O2)C1=CC=CN=C1 Chemical compound COC1=CC2=C(C=C1)N=C(O2)C1=CC=CN=C1 PAYAXQUHENCLPC-UHFFFAOYSA-N 0.000 claims description 3
- LNNFLXPFGVFQGQ-UHFFFAOYSA-N COC1=CC=C2N=C(SC2=C1)C1=C(C=CC=C1)C#N Chemical compound COC1=CC=C2N=C(SC2=C1)C1=C(C=CC=C1)C#N LNNFLXPFGVFQGQ-UHFFFAOYSA-N 0.000 claims description 3
- JFDHYZWYORPCKH-UHFFFAOYSA-N COC1=CC=C2N=C(SC2=C1)C1=C(C=CN=C1)C#N Chemical compound COC1=CC=C2N=C(SC2=C1)C1=C(C=CN=C1)C#N JFDHYZWYORPCKH-UHFFFAOYSA-N 0.000 claims description 3
- BXGSFXCTYTUNEV-UHFFFAOYSA-N COC1=CC=C2N=C(SC2=C1)C1=C(C=NC=C1)C#N Chemical compound COC1=CC=C2N=C(SC2=C1)C1=C(C=NC=C1)C#N BXGSFXCTYTUNEV-UHFFFAOYSA-N 0.000 claims description 3
- JTSQDUDQVIJBDO-UHFFFAOYSA-N COC1=CC=C2N=C(SC2=C1)C1=C(C=NC=C1)C1=CC=NN1 Chemical compound COC1=CC=C2N=C(SC2=C1)C1=C(C=NC=C1)C1=CC=NN1 JTSQDUDQVIJBDO-UHFFFAOYSA-N 0.000 claims description 3
- CJQVZZMUBSLELW-UHFFFAOYSA-N COC1=CC=C2N=C(SC2=C1)C1=C(F)C=NC=C1 Chemical compound COC1=CC=C2N=C(SC2=C1)C1=C(F)C=NC=C1 CJQVZZMUBSLELW-UHFFFAOYSA-N 0.000 claims description 3
- AZAYPOAVWWHCHY-UHFFFAOYSA-N COC1=CC=C2N=C(SC2=C1)C1=C(NC(C)=O)C=NC=C1 Chemical compound COC1=CC=C2N=C(SC2=C1)C1=C(NC(C)=O)C=NC=C1 AZAYPOAVWWHCHY-UHFFFAOYSA-N 0.000 claims description 3
- FKADLDSNMFJVBL-UHFFFAOYSA-N COC1=CC=C2N=C(SC2=C1)C1=CC(=NC=C1)C#N Chemical compound COC1=CC=C2N=C(SC2=C1)C1=CC(=NC=C1)C#N FKADLDSNMFJVBL-UHFFFAOYSA-N 0.000 claims description 3
- FKOVKIKWPKMHKM-UHFFFAOYSA-N COC1=CC=C2N=C(SC2=C1)C1=NC=CC=C1Br Chemical compound COC1=CC=C2N=C(SC2=C1)C1=NC=CC=C1Br FKOVKIKWPKMHKM-UHFFFAOYSA-N 0.000 claims description 3
- DEXVWOFONGHZLU-UHFFFAOYSA-N COC1=CC=C2N=C(SC2=C1)C1=NC=CC=C1C#N Chemical compound COC1=CC=C2N=C(SC2=C1)C1=NC=CC=C1C#N DEXVWOFONGHZLU-UHFFFAOYSA-N 0.000 claims description 3
- FANQQVRZKRJLSP-UHFFFAOYSA-N COC1=CC=C2SC(=NC2=C1)C1=C(C=NC=C1)C#N Chemical compound COC1=CC=C2SC(=NC2=C1)C1=C(C=NC=C1)C#N FANQQVRZKRJLSP-UHFFFAOYSA-N 0.000 claims description 3
- QRJWHFVSZZXVBT-UHFFFAOYSA-N COC=1C=C2C(=CN=1)OC(=C2)C1=C(C#N)C=CC=C1 Chemical compound COC=1C=C2C(=CN=1)OC(=C2)C1=C(C#N)C=CC=C1 QRJWHFVSZZXVBT-UHFFFAOYSA-N 0.000 claims description 3
- YMSHCJXAXGHIEZ-UHFFFAOYSA-N COC=1C=C2C(=CN=1)OC(=C2)C1=C(C=NC=C1)C#N Chemical compound COC=1C=C2C(=CN=1)OC(=C2)C1=C(C=NC=C1)C#N YMSHCJXAXGHIEZ-UHFFFAOYSA-N 0.000 claims description 3
- ZZXIXPMLMMJNMQ-UHFFFAOYSA-N COC=1C=C2C(=NC=1)C=C(O2)C1=C(C=NC=C1)C#N Chemical compound COC=1C=C2C(=NC=1)C=C(O2)C1=C(C=NC=C1)C#N ZZXIXPMLMMJNMQ-UHFFFAOYSA-N 0.000 claims description 3
- KGRGSTBDZQKGLP-UHFFFAOYSA-N COC=1C=C2C(=NC=1)OC(=C2)C1=C(C#N)C=CC=C1 Chemical compound COC=1C=C2C(=NC=1)OC(=C2)C1=C(C#N)C=CC=C1 KGRGSTBDZQKGLP-UHFFFAOYSA-N 0.000 claims description 3
- BTIWXOBFYVNBSH-UHFFFAOYSA-N COC=1C=C2C=CC(=CC2=CC=1)C1=C(C=NC=C1)C#N Chemical compound COC=1C=C2C=CC(=CC2=CC=1)C1=C(C=NC=C1)C#N BTIWXOBFYVNBSH-UHFFFAOYSA-N 0.000 claims description 3
- VQLFSDIGFJJPLW-UHFFFAOYSA-N COC=1C=C2C=CC(=NC2=CC=1)C1=C(C=NC=C1)C#N Chemical compound COC=1C=C2C=CC(=NC2=CC=1)C1=C(C=NC=C1)C#N VQLFSDIGFJJPLW-UHFFFAOYSA-N 0.000 claims description 3
- BNBADFXSIWBHDJ-UHFFFAOYSA-N COC=1C=CC2=C(C(=C(O2)C2=C(C=NC=C2)C#N)C)C=1 Chemical compound COC=1C=CC2=C(C(=C(O2)C2=C(C=NC=C2)C#N)C)C=1 BNBADFXSIWBHDJ-UHFFFAOYSA-N 0.000 claims description 3
- FVHDOZQXRBCSDA-UHFFFAOYSA-N COC=1C=CC2=C(C(=C(O2)C2=CC=NC=C2)C#N)C=1 Chemical compound COC=1C=CC2=C(C(=C(O2)C2=CC=NC=C2)C#N)C=1 FVHDOZQXRBCSDA-UHFFFAOYSA-N 0.000 claims description 3
- QZDWYXQGYDCPLT-UHFFFAOYSA-N COC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1 Chemical compound COC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1 QZDWYXQGYDCPLT-UHFFFAOYSA-N 0.000 claims description 3
- CSKRTMUGNLXELR-UHFFFAOYSA-N COC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C)C=1 Chemical compound COC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C)C=1 CSKRTMUGNLXELR-UHFFFAOYSA-N 0.000 claims description 3
- PHEZRYSFTMKEBX-UHFFFAOYSA-N COC=1C=CC2=C(C=C(O2)C2=C3C=NNC3=CC=C2)C=1 Chemical compound COC=1C=CC2=C(C=C(O2)C2=C3C=NNC3=CC=C2)C=1 PHEZRYSFTMKEBX-UHFFFAOYSA-N 0.000 claims description 3
- DODJIFVRNUXFOW-UHFFFAOYSA-N COC=1C=CC2=C(C=C(O2)C2=CC=C(C=N2)C#N)C=1 Chemical compound COC=1C=CC2=C(C=C(O2)C2=CC=C(C=N2)C#N)C=1 DODJIFVRNUXFOW-UHFFFAOYSA-N 0.000 claims description 3
- JDOFPKWECWIFMA-UHFFFAOYSA-N COC=1C=CC2=C(C=C(O2)C2=CC=CC(=N2)NC(C)=O)C=1 Chemical compound COC=1C=CC2=C(C=C(O2)C2=CC=CC(=N2)NC(C)=O)C=1 JDOFPKWECWIFMA-UHFFFAOYSA-N 0.000 claims description 3
- HXXBZLGLFSDKFV-UHFFFAOYSA-N COC=1C=CC2=C(C=C(O2)C2=NC=CC=C2C#N)C=1 Chemical compound COC=1C=CC2=C(C=C(O2)C2=NC=CC=C2C#N)C=1 HXXBZLGLFSDKFV-UHFFFAOYSA-N 0.000 claims description 3
- RXOBJIWSWCRZOD-UHFFFAOYSA-N COC=1C=CC2=C(C=C(O2)C=2C=CC=C3C=NNC=23)C=1 Chemical compound COC=1C=CC2=C(C=C(O2)C=2C=CC=C3C=NNC=23)C=1 RXOBJIWSWCRZOD-UHFFFAOYSA-N 0.000 claims description 3
- KRAMVQMNVWQMPY-UHFFFAOYSA-N COC=1C=CC2=C(C=C(O2)C=2N3C(SC=2C#N)=NCC3)C=1 Chemical compound COC=1C=CC2=C(C=C(O2)C=2N3C(SC=2C#N)=NCC3)C=1 KRAMVQMNVWQMPY-UHFFFAOYSA-N 0.000 claims description 3
- NVWSASNSROERBD-UHFFFAOYSA-N COC=1C=CC2=C(NC(=N2)C2=C(C=NC=C2)C#N)C=1 Chemical compound COC=1C=CC2=C(NC(=N2)C2=C(C=NC=C2)C#N)C=1 NVWSASNSROERBD-UHFFFAOYSA-N 0.000 claims description 3
- ZAZQJWHBHVWCCW-UHFFFAOYSA-N COC=1N=CC2=C(N=1)OC(=C2)C1=C(C#N)C=CC=C1 Chemical compound COC=1N=CC2=C(N=1)OC(=C2)C1=C(C#N)C=CC=C1 ZAZQJWHBHVWCCW-UHFFFAOYSA-N 0.000 claims description 3
- HVXPAFDYVYOVAB-UHFFFAOYSA-N COCCOC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1 Chemical compound COCCOC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1 HVXPAFDYVYOVAB-UHFFFAOYSA-N 0.000 claims description 3
- VKCSRDXBBMCSHD-UHFFFAOYSA-N COCOC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1 Chemical compound COCOC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1 VKCSRDXBBMCSHD-UHFFFAOYSA-N 0.000 claims description 3
- WEPBEBNKAQHWCD-UHFFFAOYSA-N COCOC=1C=CC2=C(C=C(O2)C=2C(=NN(C=2)C)C#N)C=1 Chemical compound COCOC=1C=CC2=C(C=C(O2)C=2C(=NN(C=2)C)C#N)C=1 WEPBEBNKAQHWCD-UHFFFAOYSA-N 0.000 claims description 3
- UWTVLMCEKGTOJQ-UHFFFAOYSA-N FC(F)(F)C1=CC=C2N=C(SC2=C1)C1=C(C=NC=C1)C#N Chemical compound FC(F)(F)C1=CC=C2N=C(SC2=C1)C1=C(C=NC=C1)C#N UWTVLMCEKGTOJQ-UHFFFAOYSA-N 0.000 claims description 3
- APUFLIROHQYXIP-UHFFFAOYSA-N FCCOC1=CC=C2N=C(SC2=C1)C1=C(Br)C=NC=C1 Chemical compound FCCOC1=CC=C2N=C(SC2=C1)C1=C(Br)C=NC=C1 APUFLIROHQYXIP-UHFFFAOYSA-N 0.000 claims description 3
- OBLJVNSSLFHHGV-UHFFFAOYSA-N FCCOC1=CC=C2N=C(SC2=C1)C1=C(C=NC=C1)C#N Chemical compound FCCOC1=CC=C2N=C(SC2=C1)C1=C(C=NC=C1)C#N OBLJVNSSLFHHGV-UHFFFAOYSA-N 0.000 claims description 3
- YFGFKOZEJAGKCJ-UHFFFAOYSA-N FCCOC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1 Chemical compound FCCOC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1 YFGFKOZEJAGKCJ-UHFFFAOYSA-N 0.000 claims description 3
- NHJUTGKWXPUCON-UHFFFAOYSA-N IC1=NC=NC(=C1C#N)C=1OC2=C(C=1)C=C(C=C2)OC Chemical compound IC1=NC=NC(=C1C#N)C=1OC2=C(C=1)C=C(C=C2)OC NHJUTGKWXPUCON-UHFFFAOYSA-N 0.000 claims description 3
- VEJBIHAYIMZJHR-UHFFFAOYSA-N IC=1C=NC=CC=1C=1OC2=C(C=1)C=C(C=C2)OC Chemical compound IC=1C=NC=CC=1C=1OC2=C(C=1)C=C(C=C2)OC VEJBIHAYIMZJHR-UHFFFAOYSA-N 0.000 claims description 3
- VFNPZOPZQPFUIL-UHFFFAOYSA-N OC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1 Chemical compound OC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1 VFNPZOPZQPFUIL-UHFFFAOYSA-N 0.000 claims description 3
- KXKURFMUUGHNCV-UHFFFAOYSA-N OC=1C=CC2=C(C=C(O2)C=2N3C(SC=2C#N)=NCC3)C=1 Chemical compound OC=1C=CC2=C(C=C(O2)C=2N3C(SC=2C#N)=NCC3)C=1 KXKURFMUUGHNCV-UHFFFAOYSA-N 0.000 claims description 3
- QKNYTVPNNMLYGR-UHFFFAOYSA-N OCCOC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1 Chemical compound OCCOC=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1 QKNYTVPNNMLYGR-UHFFFAOYSA-N 0.000 claims description 3
- RFBOFFLOISIHQJ-UHFFFAOYSA-N S1C(=NC2=C1C=CC=C2)C1=C(C=NC=C1)C#N Chemical compound S1C(=NC2=C1C=CC=C2)C1=C(C=NC=C1)C#N RFBOFFLOISIHQJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 102000014461 Ataxins Human genes 0.000 claims description 2
- 108010078286 Ataxins Proteins 0.000 claims description 2
- QZHDSPHIHULIJC-UHFFFAOYSA-N BrC=1C=C(C(NC=1)=O)C1=CC=2C(=NC=C(C=2)Br)O1 Chemical compound BrC=1C=C(C(NC=1)=O)C1=CC=2C(=NC=C(C=2)Br)O1 QZHDSPHIHULIJC-UHFFFAOYSA-N 0.000 claims description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
- 238000012879 PET imaging Methods 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 2
- 210000004227 basal ganglia Anatomy 0.000 claims description 2
- 238000013170 computed tomography imaging Methods 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 238000012831 peritoneal equilibrium test Methods 0.000 claims description 2
- 238000012877 positron emission topography Methods 0.000 claims description 2
- 238000003325 tomography Methods 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- SEOJCZDOSCQLJU-UHFFFAOYSA-N OCCN(C=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1)C Chemical compound OCCN(C=1C=CC2=C(C=C(O2)C2=C(C=NC=C2)C#N)C=1)C SEOJCZDOSCQLJU-UHFFFAOYSA-N 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 0 CCCC=C(*=C(*)*1)C1=I Chemical compound CCCC=C(*=C(*)*1)C1=I 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043617P | 2014-08-29 | 2014-08-29 | |
| US62/043,617 | 2014-08-29 | ||
| PCT/US2015/047427 WO2016033460A1 (en) | 2014-08-29 | 2015-08-28 | Probes for imaging huntingtin protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017528520A JP2017528520A (ja) | 2017-09-28 |
| JP2017528520A5 true JP2017528520A5 (enExample) | 2018-10-11 |
Family
ID=55400659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530972A Ceased JP2017528520A (ja) | 2014-08-29 | 2015-08-28 | ハンチントンタンパク質のイメージング用プローブ |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10907197B2 (enExample) |
| EP (1) | EP3190888B1 (enExample) |
| JP (1) | JP2017528520A (enExample) |
| KR (1) | KR20170047341A (enExample) |
| CN (1) | CN107105655A (enExample) |
| AU (2) | AU2015308709B2 (enExample) |
| BR (1) | BR112017004134A2 (enExample) |
| CA (1) | CA2959505A1 (enExample) |
| EA (1) | EA201790408A1 (enExample) |
| ES (1) | ES2818107T3 (enExample) |
| IL (1) | IL250804A0 (enExample) |
| MX (1) | MX2017002705A (enExample) |
| SG (1) | SG11201701580XA (enExample) |
| WO (1) | WO2016033460A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX386798B (es) | 2014-08-29 | 2025-03-19 | Chdi Foundation Inc | Sondas para la proyección de imagen de la proteína huntingtina. |
| KR102586736B1 (ko) | 2014-08-29 | 2023-10-11 | 씨에이치디아이 파운데이션, 인코포레이티드 | 헌팅틴을 단백질 영상화하기 위한 프로브 |
| US11071793B2 (en) | 2014-08-29 | 2021-07-27 | Chdi Foundation, Inc. | Probes for imaging huntingtin protein |
| EP3340796B1 (en) | 2015-08-28 | 2021-04-21 | CHDI Foundation, Inc. | Probes for imaging huntingtin protein |
| CN106632002A (zh) * | 2016-09-28 | 2017-05-10 | 贵州大学 | 一种依托考昔及其对照品5‑氯‑3‑(4‑(甲基磺酰基)苯基)‑2,3‑联吡啶的制备工艺 |
| GB201617339D0 (en) | 2016-10-12 | 2016-11-23 | Lytix Biopharma As | Therapeutic compounds |
| CN108178764A (zh) * | 2018-01-09 | 2018-06-19 | 天津科技大学 | 呋喃并[2,3-b]吡啶类化合物及无金属催化的合成方法 |
| WO2020176424A1 (en) | 2019-02-25 | 2020-09-03 | Chdi Foundation, Inc. | Compounds for targeting mutant huntingtin protein and uses thereof |
| AU2021322253A1 (en) * | 2020-08-06 | 2023-02-23 | Chdi Foundation, Inc. | Heterobiaryl compounds and imaging agents for imaging Huntingtin protein |
| WO2022216947A1 (en) * | 2021-04-08 | 2022-10-13 | Chdi Foundation, Inc. | Isoindolinone compounds and imaging agents for imaging huntingtin protein |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1367836A (en) * | 1918-04-29 | 1921-02-08 | Int Precipitation Co | Process for obtaining chlorids of potassium or other metals |
| US3985755A (en) * | 1972-06-02 | 1976-10-12 | E. R. Squibb & Sons, Inc. | Pyridine containing isothiocyanobenzoxazoles |
| FR2524468B1 (fr) * | 1982-04-06 | 1985-10-18 | Sandoz Sa | Nouveaux derives condenses du thiophene, leur preparation et leur utilisation comme azurants optiques |
| JPS60146877A (ja) * | 1984-01-11 | 1985-08-02 | Chisso Corp | ２―置換―６―（５―置換―２―ピリミジニル）ナフタリン |
| JPH11171886A (ja) * | 1997-12-08 | 1999-06-29 | Mitsui Chem Inc | アミジンまたはグアニジンを側鎖にもつピロリルベンズイミダゾール誘導体 |
| KR100985140B1 (ko) | 2001-12-20 | 2010-10-05 | 와이어쓰 엘엘씨 | 5-하이드록시트립타민-6 리간드로서의 인돌릴알킬아민 유도체 |
| CA2438032C (en) | 2003-03-14 | 2013-05-07 | University Of Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
| CN1784392A (zh) * | 2003-03-14 | 2006-06-07 | 匹兹堡大学 | 苯并噻唑衍生物化合物、组合物及用途 |
| JP2007504283A (ja) * | 2003-05-20 | 2007-03-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | β−アミロイド斑に作用物質を結合させる方法 |
| WO2005016384A1 (ja) * | 2003-08-13 | 2005-02-24 | Bf Research Institute, Inc. | アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤 |
| AU2007288124B2 (en) | 2006-08-24 | 2013-04-04 | Australian Nuclear Science & Technology Organisation | Fluorinated ligands for targeting peripheral benzodiazepine receptors |
| US7858803B2 (en) * | 2007-04-27 | 2010-12-28 | The General Hospital Corporation | Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders |
| KR101469275B1 (ko) | 2007-06-01 | 2014-12-08 | 재단법인서울대학교산학협력재단 | 베타아밀로이드 침착의 영상화를 위한 헤테로사이클릭 인덴계열의 유도체 및 그의 방사성 동위원소 표지화합물 |
| US20090123373A1 (en) | 2007-11-05 | 2009-05-14 | Yanming Wang | Amyloid-imaging agents |
| US8153813B2 (en) * | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
| WO2009146388A1 (en) * | 2008-05-28 | 2009-12-03 | The Trustees Of Columbia University In The City Of New York | Voxel-based methods for assessing subjects using positron emission tomography |
| AU2009260519A1 (en) | 2008-05-30 | 2009-12-23 | Merck Sharp & Dohme Corp. | Novel substituted azabenzoxazoles |
| JP2012507534A (ja) * | 2008-10-31 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | 新規置換アザベンゾオキサゾール類 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| GB0905664D0 (en) | 2009-04-02 | 2009-05-13 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| ES2548571T3 (es) | 2009-04-02 | 2015-10-19 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Derivados de imidazo[2,1-b][1,3,4]tiadiazol |
| EP2501696B1 (en) * | 2009-10-15 | 2016-12-28 | Guerbet | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
| JP2011168515A (ja) | 2010-02-17 | 2011-09-01 | Kowa Co | エリスロポエチン産生促進作用を有する２−アリールベンゾオキサゾール化合物 |
| MX386798B (es) | 2014-08-29 | 2025-03-19 | Chdi Foundation Inc | Sondas para la proyección de imagen de la proteína huntingtina. |
| US11071793B2 (en) | 2014-08-29 | 2021-07-27 | Chdi Foundation, Inc. | Probes for imaging huntingtin protein |
| KR102586736B1 (ko) | 2014-08-29 | 2023-10-11 | 씨에이치디아이 파운데이션, 인코포레이티드 | 헌팅틴을 단백질 영상화하기 위한 프로브 |
| EP3340796B1 (en) | 2015-08-28 | 2021-04-21 | CHDI Foundation, Inc. | Probes for imaging huntingtin protein |
-
2015
- 2015-08-28 CA CA2959505A patent/CA2959505A1/en not_active Abandoned
- 2015-08-28 WO PCT/US2015/047427 patent/WO2016033460A1/en not_active Ceased
- 2015-08-28 ES ES15836157T patent/ES2818107T3/es active Active
- 2015-08-28 BR BR112017004134A patent/BR112017004134A2/pt not_active Application Discontinuation
- 2015-08-28 SG SG11201701580XA patent/SG11201701580XA/en unknown
- 2015-08-28 EA EA201790408A patent/EA201790408A1/ru unknown
- 2015-08-28 US US15/507,217 patent/US10907197B2/en active Active
- 2015-08-28 JP JP2017530972A patent/JP2017528520A/ja not_active Ceased
- 2015-08-28 MX MX2017002705A patent/MX2017002705A/es unknown
- 2015-08-28 KR KR1020177008352A patent/KR20170047341A/ko not_active Ceased
- 2015-08-28 CN CN201580058281.9A patent/CN107105655A/zh active Pending
- 2015-08-28 AU AU2015308709A patent/AU2015308709B2/en active Active
- 2015-08-28 EP EP15836157.6A patent/EP3190888B1/en active Active
-
2017
- 2017-02-27 IL IL250804A patent/IL250804A0/en unknown
-
2020
- 2020-03-30 AU AU2020202226A patent/AU2020202226A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529340A5 (enExample) | ||
| HRP20211778T1 (hr) | Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina | |
| JP2017528519A5 (enExample) | ||
| US10907197B2 (en) | Probes for imaging huntingtin protein | |
| JP2009541309A5 (enExample) | ||
| JP2013516393A5 (enExample) | ||
| HRP20220001T1 (hr) | Sonde za snimanje huntingtin proteina | |
| JP2018531897A5 (enExample) | ||
| JP2008133297A5 (enExample) | ||
| JP2014510747A5 (enExample) | ||
| CA2959531C (en) | Probes for imaging huntingtin protein | |
| PE20120774A1 (es) | COMPUESTOS DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINDIONA COMO MODULADORES DE TRPA1 | |
| RU2018110055A (ru) | Зонды визуализации белка гентингтина | |
| JP2019522018A5 (enExample) | ||
| PL3548026T3 (pl) | 5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion do leczenia niealkoholowej stłuszczeniowej choroby wątroby | |
| HK1241223B (en) | Probes for imaging huntingtin protein | |
| HK1241223A1 (en) | Probes for imaging huntingtin protein | |
| HK1240583B (en) | Probes for imaging huntingtin protein |